Ga. Comp. R. & Regs. 480-19-.03

Current through Rules and Regulations filed through November 21, 2024
Rule 480-19-.03 - Over-thecounter (OTC) Sales of Exempt Schedule V Controlled Substance Drug Products Containing Pseudoephedrine
(a) No person shall obtain or attempt to obtain, sell, dispense or otherwise distribute any exempt Schedule V controlled substance drug product containing pseudoephedrine as listed under O.C.G.A. 16-13-29(5), except as herein provided, and as in compliance with all other applicable state or federal laws, rules and regulations. All terms used in this section shall have the same meaning as in O.C.G.A. T.16, Ch. 13 and T. 26, Ch. 4.
1) All exempt Schedule V controlled substance pseudoephedrine containing drug products must be stored in a pharmacy's prescription department.
2) All pharmacy personnel who engage in the sale or distribution of exempt Schedule V controlled substance containing drug products must complete the DEA's self-certification training as required by the Combat Methamphetamine Epidemic Act of 2005, 21 U.S.C. 830.
(b) A registered pharmacist or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may sell, dispense or otherwise dispose of without prescription not more than 3.6 grams every 24 hours, or a maximum of 9 grams every 30 days, to each customer of a pseudoephedrine containing drug product, but only:
1) After applying reasonable means or effort to determine that such is to be used for legitimate medical purposes, following the proper record keeping procedures, and ensuring the required information has been properly recorded in a logbook which contains either a written or electronic list of sales.
2) For hand-written logbooks used to record patient information before the sale of an exempt Schedule V pseudoephedrine containing drug product can take place:
(A) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist, must approve all such sales or transactions. Approval means verifying the patient's identification and ensuring the patient has a valid reason for obtaining the pseudoephedrine. After approval, the registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may direct designated pharmacy personnel, to complete any sales transactions to a patient by writing in the logbook at a minimum the name of the pseudoephedrine containing drug product, strength, and quantity sold along with the name of the patient, their date of birth, address, zip code, data and time of sale; The pharmacy may require additional patient information for the logbook as long as the required information is obtained.
(B) The patient must sign the logbook to acknowledge the sale and receipt of the pseudoephedrine containing drug product.
(C) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may personally, or may direct designated pharmacy to, ask the patient to produce a photo identification issued by a state or the federal government to use in verifying that the patient's name on the photo identification matches the name the patient wrote in the logbook; No exempt Schedule V pseudoephedrine containing drug product can be sold to a patient unless they present appropriate identification
(D) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist must or may direct designated pharmacy personnel to verify that the date and time of the sale and other information that has been entered in the logbook is correct by use of the patient's photo identification, and initial the logbook verifying the information for the sale as being correct.
3) For electronic logbooks used to record patient information for the sale of an exempt Schedule V pseudoephedrine containing drug product:
(A) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist, must approve all such sales or transactions. Approval means verifying the patient's identification and ensuring the patient has a valid reason for obtaining the pseudoephedrine. After approval, the registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may direct designated pharmacy personnel, to complete any sales transactions to a patient by entering, at a minimum, the name of the pseudoephedrine containing drug product, strength, and quantity sold; the patient's name, date of birth, address, and zip code, or entering this information may be accomplished through a point of sales system and bar code reader. The pharmacy may require additional patient information for the logbook as long as the required information is obtained.
(B) The computer for the electronic logbook can automatically enter the date and time of the sale,
(C) The patient's signature on the logbook must be captured using an electronic signature system of a type similar to or one used for credit card purchases
(D) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may personally, or may direct designated pharmacy personnel to, must ask the patient to produce a photo identification issued by a state or the federal government to use in verifying that the patient's name on the photo identification matches the name the patient wrote in the logbook; No exempt Schedule V pseudoephedrine containing drug product can be sold to a patient unless they present appropriate photo identification
(E) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist must, or may direct designated pharmacy personnel to, enter their name or pharmacist, pharmacy intern license number, or pharmacy personnel's identification in the logbook to indicate the information for the sale is correct.
(4) The quantities of different strength pseudoephedrine containing drug products that equals 3.6 grams is:

Tablets/capsules - Number of tablets/capsules that equal 3.6 grams

IngredientsNumber of tablets = 3.6 grams

30 mg Pseudoephedrine HCl

146 Tablets

60 mg Pseudoephedrine HCl

73 Tablets

120 mg Pseudoephedrine HCl

36 Tablets

30 mg Pseudoephedrine Sulfate

155 Tablets

60 mg Pseudoephedrine Sulfate

77 Tablets

120 mg Pseudoephedrine Sulfate

38 Tablets

240 mg Pseudoephedrine Sulfate

19 Tablets

Liquids -Number of milliliters that equal 3.6 grams

Ingredients

Number of milliliters (ml) = 3.6 grams

6.25 mg Ephedrine HCl/ 5 ml Liquid

3515 ml

15 mg Pseudoephedrine HCl / 1.6 ml Liquid

468 ml

7.5 mg Pseudoephedrine HCl / 5 ml Liquid

2929 ml

15 mg Pseudoephedrine HCl / 5 ml Liquid

1464 ml

15 mg Pseudoephedrine HCl / 2.5 ml Liquid

732 ml

30 mg Pseudoephedrine HCl / 5 ml Liquid

732 ml

30 mg Pseudoephedrine HCl / 2.5 ml Liquid

366 ml

60 mg Pseudoephedrine HCl / 5 ml Liquid

366 ml

(c) No registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist can knowingly sell more than 9 grams of pseudoephedrine to a patient in a 30 day period of time.
(1) The quantities of different strength pseudoephedrine containing drug products that equals 9 grams is:

Tablets/capsules - Number of tablets/capsules that equal 9 grams

Ingredients

Number of tablets = 9 grams

30 mg Pseudoephedrine HCl

366 Tablets

60 mg Pseudoephedrine HCl

183 Tablets

120 mg Pseudoephedrine HCl

91 Tablets

30 mg Pseudoephedrine Sulfate

389 Tablets

60 mg Pseudoephedrine Sulfate

194Tablets

120 mg Pseudoephedrine Sulfate

97 Tablets

240 mg Pseudoephedrine Sulfate

48 Tablets

Liquids -Number of milliliters in 9 grams

Ingredients

Number of milliliters (ml) = 9 grams

6.25 mg Ephedrine HCl / 5 ml Liquid

8788 ml

15 mg Pseudoephedrine HCl / 1.6 ml Liquid

1171 ml

7.5 mg Pseudoephedrine HCl / 5 ml Liquid

7323 ml

15 mg Pseudoephedrine HCl / 5 ml Liquid

3661 ml

15 mg Pseudoephedrine HCl / 2.5 ml Liquid

1830 ml

30 mg Pseudoephedrine HCl / 5 ml Liquid

1830 ml

30 mg Pseudoephedrine HCl / 2.5 ml Liquid

915 ml

60 mg Pseudoephedrine HCl / 5 ml Liquid

915 ml

(d) All logbooks must be retained for a minimum period of 2 years from the date of the last recorded sale.
(e) Logbooks must be kept in a secure location in the pharmacy and information contained in a logbook can be shared:
(A) To comply with state or federal laws and rules;
(B) For a product recall
(C) With local, state, and federal law enforcement officers, to allow logbook information to be inspected, copied.
(f) Nothing in this rule would prohibit pharmacies, or 3rd party information technology company acting on behalf of a pharmacy, to report or transmit sales data for exempt Schedule V controlled substance drug products containing pseudoephedrine to the state operated central registry, also known as the Georgia Methamphetamine Information System (GMIS). Without approval from GDNA, such data cannot be reported to any other central record keeping system. These sales may be reported to the registry either electronically, by means of transmitting a faxed copy of a handwritten logbook, or by sending copies of handwritten logbooks to the GDNA designated collection location for the registry via the U.S. mail or other similar means.
(g) Nothing in this rule requires a pharmacy to maintain a logbook that is separate and apart from the logbook required under the U.S. Combat Methamphetamine Epidemic Act of 2005, 21 U.S.C 830 and 844, other than drug products containing pseudoephedrine must be stored in the prescription department area of a pharmacy and the sales are made by a registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist.

Ga. Comp. R. & Regs. R. 480-19-.03

O.C.G.A. §§ 16-13-22, 16-13-29, 16-13-29.2, 16-13-34, 26-4-27, 26-4-28.

Original Rule entitled "Over-the-counter (OTC) Sales of Exempt Schedule V Controlled Substance Drug Products containing Pseudoephedrine" adopted. F. Nov. 28, 2011; eff. Dec. 18, 2011.